3-異丁基-1-甲基黃嘌呤

生物活性靶點(diǎn)體外研究體內(nèi)研究 用途與合成方法 MSDS 3-異丁基-1-甲基黃嘌呤價(jià)格(試劑級(jí)) 上下游產(chǎn)品信息

中文名稱	3-異丁基-1-甲基黃嘌呤
中文同義詞	3-異丁基-1-甲基-2,6(1H,3H)-嘌呤二酮;3-異丁基-1-甲基黃嘌呤(IBMX),99%;3-ISOBUTYL-1-METHYLXANTHINE 3-異丁基-1-甲基黃嘌呤 IBMX;3-異丁基-1-甲基黃嘌呤(IBMX、1-甲基-3-異丁基黃嘌呤、3,7-二氫-3-異丁基-1-甲基-1H-嘌呤-2,6-二酮);3-異丁基-1-甲基-1H-嘌呤-2,6(3H,9H)-二酮;3-異丁基-1-甲基-3,9-二氫-1H-嘌呤-2,6-二酮;IBMX、1-甲基-3-異丁基黃嘌呤;3-異丁基-1-甲基黃嘌呤(IBMX)
英文名稱	3-ISOBUTYL-1-METHYLXANTHINE
英文同義詞	1H-Purine-2,6-dione, 3,7-dihydro-1-methyl-3-(2-methylpropyl)-;3,7-dihydro-1-methyl-3-(2-methylpropyl)-1h-purine-6-dione;3-Isobutyl-1-methyl-3,7-dihydro-1H-purine-2,6-dione;3-Isobutyl-1-methylanxthine;3-isobutyl-1-methyl-xanthin;IMX;Isobutylmethylxanthine;Methylisobutylxanthine
CAS號(hào)	28822-58-4
分子式	C10H14N4O2
分子量	222.24
EINECS號(hào)	249-259-3
相關(guān)類別	生化試劑;小分子抑制劑;嘌呤;有機(jī)砌塊;其他生化試劑;雜環(huán)砌塊;其他化學(xué)試劑;科研試劑;標(biāo)準(zhǔn)品;其它;原料;Inhibitors;All Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
Mol文件	28822-58-4.mol
結(jié)構(gòu)式

3-異丁基-1-甲基黃嘌呤 性質(zhì)

3-異丁基-1-甲基黃嘌呤 用途與合成方法

生物活性

IBMX (Isobutylmethylxanthine, 1-Methyl-3-Isobutylxanthine)是一種非特異性phosphodiesterase (PDE)抑制劑，對(duì)PDE3、PDE4、PDE5的IC50值分別為6.5±1.2, 26.3±3.9 和 31.7±5.3 μM。它能增強(qiáng)細(xì)胞內(nèi)cAMP水平，是adenosine (A1) receptor拮抗劑。

靶點(diǎn)

體外研究

At 100 μM, KMUP-1 (a xanthine derivative) and IBMX are the most effective at inducing tracheal relaxation; the magnitude of the relaxation responses induced by KMUP-1 and IBMX are not significantly different. IBMX (100 μM) activates renal outer medullary K     ⁺    (ROMK) channels (n=6, P<0.05) and prevents further channel activation by ANG II (n=6, P=NS) or cGMP. Of note is that pretreatment of cortical collecting duct (CCDs) isolated from high-K  ⁺    (HK)-fed rats with IBMX (100 μM) for 20 min leads to a significant increase in tubular cAMP content to 1.43±0.35 pg/mm tubule length (n=14) compare with that measured in vehicle-treated controls (0.61±0.13 pg/mm tubule length, n=12, P<0.05).

體內(nèi)研究

IBMX, a non-selective PDE inhibitor significantly decreases the liver glycogen storage (mg/g, IBMX 22±1.5 P<0.001). In comparison with the control group, IBMX and mc5 significantly increase plasma glucose (blood glucose, mg/dl, control=141±3, IBMX=210±17 P<0.001 and mc5=191±13 P<0.01) while other test compounds (mc1, mc6, MCPIP and Win 47203) do not produce significant effect (control=141±3, mc1 160±7, mc6 175±9, MCPIP 179±8 and Win 47203 116±2 P>0.05) also mc2 does not change plasma glucose (control=141±3 and mc2=145±5). IBMX has the highest efficacy on increasing plasma glucose. Treatments with IBMX and Apocynin significantly decrease cold-induced elevation of right ventricular (RV) systolic pressure (23.5±1.8 and 24.2±0.6 mmHg, respectively) although they do not decrease RV pressure to the warm control levels. IBMX or Apocynin significantly reduces medial layer thickness (19.0±0.9, and 16.9±0.8 μm, respectively) and increases lumen diameter (62.7±4.2, and 59.5±4.3 μm, respectively) of small PAs in cold-exposed rats.

用途 

環(huán)核苷酸磷酸二酯酶蛋白抑制劑。

用途 

cAMP 和 cGMP 磷酸二脂酶的非專一性抑制劑。IBMX抑制了磷酸二脂酶，cAMP的增加激活了PKA ，其結(jié)果是減少增殖，增加分化和誘發(fā)凋亡. IBMX抑制由苯腎上腺素誘導(dǎo)的色胺（來(lái)自于神經(jīng)內(nèi)分泌上皮細(xì)胞的減少粘液IC50: 1.3 μM）的減少 。也作為腺苷受體拮抗劑。

安全信息

MSDS信息

3-異丁基-1-甲基黃嘌呤 價(jià)格(試劑級(jí))

3-異丁基-1-甲基黃嘌呤 上下游產(chǎn)品信息